We have located links that may give you full text access.
Exploring salivary iodine concentration as a biomarker for iodine status and thyroid nodules in females from different water iodine areas: a cross-sectional study.
American Journal of Clinical Nutrition 2024 April 25
BACKGROUND: It is unclear whether salivary iodine concentration (SIC) can assess iodine status in females from different water iodine regions.
OBJECTIVE: Through a cross-sectional study, we explored the feasibility of SIC as a biomarker to assess iodine status in females and develop optimal cut-off values.
METHODS: A total of 1991 females were analyzed in this cross-sectional study from the coastal iodine-deficient areas (CIDA), inland iodine-deficient areas (IIDA), iodine-adequate areas (IAA), iodine-excess areas (IEA), and iodine extra-high areas (IEHA). SIC, spot urine iodine concentration(SUIC), and daily total iodine intake (TII) were assessed, and ultrasonography was performed in all subjects.
RESULTS: There was a positive correlation between SIC and SUIC (r = 0.67, 95% CI: 0.64-0.69, P < 0.001), and TII (r = 0.47, 95% CI: 0.43-0.50, P < 0.001). The prevalence of thyroid nodules (TN) showed an upward trend with SIC increasing (Z = -2.83, P for trend =0.005). The area under the receiver-operating characteristic (ROC) curve for SIC to assess iodine deficiency was 0.62 (95% CI: 0.60-0.65, P < 0.001) and 0.75 (95% CI: 0.73-0.77, P < 0.001) for iodine excess. The cut-off values were: SIC<93.32 μg/L, iodine deficiency; 93.32-224.60 μg/L, iodine adequacy; >224.60 μg/L, iodine excess. When SIC>224.60 μg/L, the odds ratio (OR) for UIC>300 μg/L, excessive TII, and the prevalence of TN were 6.44, 3.68, and 1.27 (95% CI: 4.98-8.31, 2.83-4.79, 1.02-1.56, respectively; P < 0.05); when SIC<93.32 μg/L, the OR for UIC<100 μg/L and insufficient TII were 2.34, and 1.94 (95% CI: 1.73-3.14, 1.33-2.83; P < 0.05).
CONCLUSIONS: Using SIC as a biomarker, females in CIDA exhibited mild iodine deficiency, those in IIDA and IAA demonstrated moderate iodine deficiency, and those in IEA and IEHA exhibited an excess of iodine, consistent with SUIC to assess iodine status. SIC can be used as a good biomarker to evaluate the iodine status in population.
OBJECTIVE: Through a cross-sectional study, we explored the feasibility of SIC as a biomarker to assess iodine status in females and develop optimal cut-off values.
METHODS: A total of 1991 females were analyzed in this cross-sectional study from the coastal iodine-deficient areas (CIDA), inland iodine-deficient areas (IIDA), iodine-adequate areas (IAA), iodine-excess areas (IEA), and iodine extra-high areas (IEHA). SIC, spot urine iodine concentration(SUIC), and daily total iodine intake (TII) were assessed, and ultrasonography was performed in all subjects.
RESULTS: There was a positive correlation between SIC and SUIC (r = 0.67, 95% CI: 0.64-0.69, P < 0.001), and TII (r = 0.47, 95% CI: 0.43-0.50, P < 0.001). The prevalence of thyroid nodules (TN) showed an upward trend with SIC increasing (Z = -2.83, P for trend =0.005). The area under the receiver-operating characteristic (ROC) curve for SIC to assess iodine deficiency was 0.62 (95% CI: 0.60-0.65, P < 0.001) and 0.75 (95% CI: 0.73-0.77, P < 0.001) for iodine excess. The cut-off values were: SIC<93.32 μg/L, iodine deficiency; 93.32-224.60 μg/L, iodine adequacy; >224.60 μg/L, iodine excess. When SIC>224.60 μg/L, the odds ratio (OR) for UIC>300 μg/L, excessive TII, and the prevalence of TN were 6.44, 3.68, and 1.27 (95% CI: 4.98-8.31, 2.83-4.79, 1.02-1.56, respectively; P < 0.05); when SIC<93.32 μg/L, the OR for UIC<100 μg/L and insufficient TII were 2.34, and 1.94 (95% CI: 1.73-3.14, 1.33-2.83; P < 0.05).
CONCLUSIONS: Using SIC as a biomarker, females in CIDA exhibited mild iodine deficiency, those in IIDA and IAA demonstrated moderate iodine deficiency, and those in IEA and IEHA exhibited an excess of iodine, consistent with SUIC to assess iodine status. SIC can be used as a good biomarker to evaluate the iodine status in population.
Full text links
Related Resources
Trending Papers
Drug-Induced Myocardial Infarction: A Review of Pharmacological Triggers and Pathophysiological Mechanisms.Journal of Cardiovascular Development and Disease 2024 December 18
Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (Version 3: Revised May 20th, 2024).Clinical and Experimental Nephrology 2025 January 3
The PRECISE trial: How should patients with chest pain be tested?Cleveland Clinic Journal of Medicine 2024 November 1
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app